Lightnews — Scholar-powered news

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 3h

Researchers at Yale School of Medicine and The University of Queensland have developed a spatial biology–driven “Google Maps” approach to predict how non-small cell lung cancer (NSCLC) responds to therapy. #lungcancer
medicine.yale.edu/news-article...

‘Google Maps’ Approach to Revolutionize Lung Cancer Treatment

The work provides a road map for new diagnostic tests that could optimize treatment choice.

medicine.yale.edu

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 1d

Activating the NRF2E79Q mutation reshapes the differentiation trajectory of non-small cell lung cancer (NSCLC). Results were published in Cancer Gene Therapy (CGT). #lungcancer
www.nature.com/articles/s41...

Activating NRF2E79Q mutation alters the differentiation of human non-small cell lung cancer - Cancer Gene Therapy

Cancer Gene Therapy - Activating NRF2E79Q mutation alters the differentiation of human non-small cell lung cancer

www.nature.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 2d

A global Phase 3 trial is underway to test ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug conjugate, as a potential new standard for relapsed small cell lung cancer (SCLC). #lungcancer
www.tandfonline.com/doi/full/10....

IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer

IDeate-Lung02 will ascertain whether I-DXd treatment after only one prior line of systemic treatment improves outcomes for patients with relapsed SCLC compared with topotecan, amrubicin, or lurbinectedin.

www.tandfonline.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 3d

AZD4625 study uncovers mTOR signaling as a key driver of primary resistance in KRAS-G12C NSCLC. #lungcancer
www.nature.com/articles/s41...

Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms - British Journal of Cancer

British Journal of Cancer - Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms

www.nature.com

1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 4d

Congratulations to Dr. Benjamin Levy and colleagues at Johns Hopkins Hospital! The phase 3 NeoADAURA study has established neoadjuvant osimertinib as a new benchmark for patients with resectable EGFR-mutated NSCLC, challenging the established standard of care. #lungcancer

Targeted Therapies Move the Needle in NSCLC | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

www.onclive.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 5d

Exciting research! Amivantamab plus lazertinib is the first targeted, chemotherapy-free regimen to show a survival advantage over osimertinib in frontline EGFR-mutated non-small cell lung cancer. #lungcancer
www.oncologynewscentral.com/nsclc/chemot...

Chemotherapy-Free Combo Prolongs Survival in EGFR-Mutated Non-Small Cell Lung Cancer

The findings were based on the final protocol-specified analysis of the phase 3 MARIPOSA trial.

www.oncologynewscentral.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 6d

Congratulations to Boehringer Ingelheim! The company released new lung cancer findings at ESMO 2025. #lungcancer
www.boehringer-ingelheim.com/us/human-hea...

Boehringer Ingelheim presents latest research in lung cancer at ESMO 2025, demonstrating strength of oncology portfolio

Late-breaking data from Phase Ib Beamion LUNG-1 trial evaluating HERNEXEOS® (zongertinib tablets) as a first-line therapy for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer to be presented.

www.boehringer-ingelheim.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 8d

New research alert! Dual immune checkpoint blockade significantly improves overall survival in those with PD-L1 TPS <1% and those with an STK11 mutation. #lungcancer

www.thelancet.com

1 1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 8d

Please consider referring your small cell lung cancer patients to the SUCCEED Study. Now enrolling! #lungcancer #sclc #clinicaltrials alcmi.org/succeed

1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 9d

Congratulations to the lung cancer team at Montefiore Einstein Comprehensive Cancer Center, a member of the ALCMI consortium, for earning international recognition from the IASLC for its outstanding contributions to thoracic oncology care! #lungcancer

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition - The Cancer Letter

Montefiore Einstein Comprehensive Cancer Center announced that its lung cancer team has been recognized by the International Association for the Study of Lung Cancer for delivering outstanding care.…

cancerletter.com

1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 10d

Great news! The FDA has approved the first and only combination therapy for first-line maintenance in extensive-stage small cell lung cancer. #lungcancer
www.reuters.com/business/hea...

Jazz Pharma, Roche's combination therapy for lung cancer gets US approval

Jazz's drug, Zepzelca, in combination with Roche's Tecentriq, is now approved for patients with extensive-stage small cell lung cancer (ES-SCLC), whose disease has not progressed after initial chemotherapy.

www.reuters.com

2

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 11d

Congratulations to Dr. Tikvah Hayes on receiving a $600,000 V Scholar Program grant from the V Foundation for Cancer Research to advance treatment strategies for EGFR-mutant lung cancer! #lungcancer
www.uclahealth.org/news/release...

Dr. Tiki Hayes awarded grant to help unlock treatments for EGFR-mutant lung cancer

The new funding will support Hayes in developing new lab models using human lung cells and 3D organoids to better understand how these rare EGFR mutations drive cancer growth.

www.uclahealth.org

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 12d

At the ASTRO 2025 Annual Meeting, Dr. Joshua Meyer and colleagues at Fox Chase Cancer Center presented phase I trial results showing that pulsed low dose rate (PLDR) radiation significantly reduces toxicity without compromising efficacy. #lungcancer

Newer Radiation Technique Reduces Side Effects While Maintaining Effectiveness

Researchers at Fox Chase Cancer Center have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for…

www.foxchase.org

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 13d

Stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer (NSCLC), according to MD Anderson Cancer Center's Dr. Joe Chang and the STARS trial. #lungcancer
www.cancernetwork.com/view/radiati...

Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC | CancerNetwork

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

www.cancernetwork.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 14d

Lung cancer now boasts one of the most robust portfolios of actionable biomarkers in oncology, according to Ed Kim, MD, MBA, and Neel Shah, MD. #lungcancer
www.targetedonc.com/view/navigat...

Navigating Modern Lung Cancer Treatment and Clinical Trial Access | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians in the Treating Together podcast.

www.targetedonc.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 15d

Zipalertinib, an oral EGFR TKI, has demonstrated clinically meaningful efficacy with a manageable safety profile in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer, according to Helena Yu, MD, from Memorial Sloan Kettering Cancer Center. #lungcancer

The Landscape of EGFR Exon 20-Positive Lung Cancer Treatment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Discover how zipalertinib, an oral TKI, addresses unmet needs in treating EGFR exon 20 insertion-mutated non-small cell lung cancer.

www.targetedonc.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 16d

Kwame Adjei, PharmD, Ph.D., Vakaramoko Diaby, Meng Li, Fatimah Sherbeny, PharmD, MS, PhD, Sandra Suther, and Askal Ali have delivered the most comprehensive synthesis to date on how real option value (ROV) is being applied to oncology. #lungcancer
pubmed.ncbi.nlm.nih.gov/41004207/

A systematic review of the applications of the real option value of medical technologies in oncology - PubMed

The ROV represents a critical dimension in evaluating medical technologies in oncology, where innovation is rapid. The implications of ROV extend beyond oncology, with the potential to influence…

pubmed.ncbi.nlm.nih.gov

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 17d

The nihilism surrounding SCLC is being dismantled by data, biology, and a renewed commitment to inclusive research. #lungcancer
www.cancernetwork.com/view/overcom...

Overcoming the “Nihilism” Surrounding the Small Cell Lung Cancer Prognosis | CancerNetwork

Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.

www.cancernetwork.com

1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 18d

Patients with poor performance status, who represent up to 88% of real-world cases, are routinely excluded from the pivotal trials that defined chemoimmunotherapy as the standard of care. #lungcancer
www.thelancet.com/journals/lan...

Rethinking immunotherapy in patients with SCLC with poor performance status

The addition of immune checkpoint inhibitors (ICI) to first-line platinum-doublet chemotherapy has substantially improved long-term outcomes in a subset of patients with extensive-stage small-cell…

www.thelancet.com

1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 19d

In a retrospective study from Saitama Medical Center, Saitama Medical University evaluated 74 patients with ECOG-PS 2–3 and found that adding an immune checkpoint inhibitor to platinum-based doublet chemotherapy increased median overall survival from 169 to 446 days. #lungcancer

Real-World Evidence Supports Chemoimmunotherapy in ES-SCLC With Poor PS | AJMC

Atezolizumab or durvalumab, combined with platinum-doublet regimens, delivered superior responses and survival in patients often excluded from clinical trials.

www.ajmc.com

1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 20d

In a real-world cohort study led by Kirsi Hormalainen and colleagues at Tampere University Hospital, comprehensive genomic profiling revealed clinically actionable mutations in 45% of NSCLC cases. #lungcancer
pubmed.ncbi.nlm.nih.gov/41015991/

Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer: A Real-World Cohort Study in Finland - PubMed

CGP affects the treatment strategies for NSCLC. Nearly half of our entire cohort had a genetic alteration eligible for approved targeted therapies. Besides these findings, CGP provides additional…

pubmed.ncbi.nlm.nih.gov

1

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 21d

In Cancer Discovery, Rocio Sotillo, PhD, and colleagues from the DKFZ German Cancer Research Center and Stanford University found that the specific variant of the EML4-ALK fusion in lung cancer dictates tumor aggression and response to targeted therapies.
medicalxpress.com/news/2025-09...

Not all ALK fusions act the same: Variants influence treatment success in lung cancer

About 5% of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now,…

medicalxpress.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 22d

Andrea Eleazar, MHS, and Kelly Paulson, MD, PhD, report in Targeted Oncology on results from the phase 1b DeLLphi-303 trial evaluating tarlatamab in combination with PD-L1 checkpoint inhibitors as maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC).

Breakthroughs in ES-SCLC Immunotherapy: The DeLLphi-303 Study | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

New research highlights the promising combination of tarlatamab and checkpoint inhibitors, showing improved survival rates in extensive-stage small cell lung cancer patients.

www.targetedonc.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 23d

Dr. Adrien Rousseau, and colleagues at ALCMI consortium member Gustave Roussy have found that some medications taken at the beginning of immunotherapy can negatively impact survival in NSCLC patients. #lungcancer
www.managedhealthcareexecutive.com/view/common-...

Common Medications Linked to Worse Survival in Lung Cancer Patients Receiving Keytruda

Patients with advanced non-small cell lung cancer were negatively affected by exposure to antibiotics, PPIs, and high-dose steroids at the start of treatment with Keytruda (pembrolizumab), French…

www.managedhealthcareexecutive.com

Addario Lung Cancer Medical Institute (ALCMI) @alcmi.bsky.social · 24d

In an interview with Cancer Network, Anne Chiang, MD, PhD, at the Yale School of Medicine, described the ongoing SWOG S2409 PRISM trial, which she chairs. #lungcancer
www.cancernetwork.com/view/underst...

Understanding and Managing Disease Heterogeneity in Small Cell Lung Cancer | CancerNetwork

In the SWOG S2409 PRISM trial, over 800 patients with small cell lung cancer will receive different treatment regimens based on their disease subtype.

www.cancernetwork.com